Wren Therapeutics Ltd. chirped about its £18 million (US$23.3 million) series A round, raised from an international syndicate led by the Baupost Group with participation from Lifeforce Capital and high net worth individuals. The Cambridge, U.K.-based company, a 2016 spinout from the University of Cambridge and Sweden's Lund University, declined to warble about the details, but Wren is known to be focused on protein misfolding diseases – a broad development area where it has its pick of some four dozen indications.